FGF-19, human recombinant protein
Human FGF-19 is encoded by the FGF19 gene. FGF-19 belongs to the FGF-19 subfamily which has three members FGF-19, 21, 23. FGFs are classically considered to be paracrine factors and are known for their roles in tissue patterning and organogenesis during embryogenesis. By contrast, the FGF-19 subfamily has recently been shown to function in an endocrine manner. Members of this subfamily have poor ability of binding to heparin binding site which is a crucial factor in ligand-receptor complex formation. β-Klotho has been identified as co-factor required for FGF-19, 21, 23 signaling. It can obviously increase ligand-receptor affinity. Unlike most FGFs which bind to and activate more than one FGF receptor, FGF19 is a specific ligand for FGF R4. In FGF-19 transgenic mice, reducing liver triglycerides, increasing fatty acid oxidation, reducing glucose levels and improving insulin sensitivity can be observed.
Reference:
1. Ladher RK, Anakwe KU, Gurney AL, et al. 2000. Science. 290:1965-7
2. Tomlinson E, Fu L, John L, et al. 2002. Endocrinology. 143:1741-7
3. Smallwood PM, Munoz-Sanjuan I, Tong P, et al. 1996. Proc Natl Acad Sci U S A. 93:9850-7
4. Fu L, John LM, Adams SH, et al. 2004. Endocrinology. 145:2594-603
5. Kharitonenkov A, Shiyanova TL, Koester A, et al. 2005. J Clin Invest. 115:1627-35
6. Kurosu H, Kuro OM. 2009. Mol Cell Endocrinol. 299:72-8
7. Lin BC, Wang M, Blackmore C, et al. 2007. J Biol Chem. 282:27277-84
8. Kharitonenkov A, Dunbar JD, Bina HA, et al. 2008. J Cell Physiol. 215:1-7.
|
Gene ID |
9965 |
|
Accession # |
O95750 |
|
Alternate Names |
|
|
Source |
Escherichia coli. |
|
M.Wt |
Approximately 21.8 kDa, a single non-glycosylated polypeptide chain containing 195 amino acids. |
|
AA Sequence |
MRPLAFSDAG PHVHYGWGDP IRLRHLYTSG PHGLSSCFLR IRADGVVDCA RGQSAHSLLE IKAVALRTVA IKGVHSVRYL CMGADGKMQG LLQYSEEDCA FEEEIRPDGY NVYRSEKHRL PVSLSSAKQR QLYKNRGFLP LSHFLPMLPM VPEEPEDLRG HLESDMFSSP LETDSMDPFG LVTGLEAVRS PSFEK |
|
Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
|
Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
|
Formulation |
Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4. |
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
|
Biological Activity |
Assay #1: Fully biologically active when compared to standard. The biological activity is measured by its binding ability in a functional ELISA. Immobilized rHuFGF R4 at 5 µg/ml can bind rHuFGF-19 with a linear range of 3-200 ng/ml. Assay #2: Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 150 ng/ml, corresponding to a specific activity of > 6.7 × 103 IU/mg. |
|
Shipping Condition |
Gel pack. |
|
Handling |
Centrifuge the vial prior to opening. |
|
Usage |
For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 95 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/µg of rHuFGF-19 as determined by LAL method.
Related Biological Data
Related Biological Data
